Trispecific binding proteins and methods of use
Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
1. A method for the treatment of a proliferative disease in an individual, comprising administrating a trispecific antigen-binding protein to the individual in need thereof, wherein said protein comprises
(a) a first domain (A) which comprises a single chain variable fragment (scFv) that specifically binds to human CD3;
(b) a second domain (B) which comprises a single domain antibody (sdAb) that binds human serum albumin; and
(c) a third domain (C) which comprises a sdAb that specifically binds to a target tumor antigen that is EGFR, PSMA, HER2, or MSLN, wherein the domains are linked in the order H 2 N—(C)—(B)—(A)—COOH, or by linkers L1 and L2, and wherein the protein is less than about 60 kDa.
2. The method according to claim 1 , wherein the proliferative disease is a cancer.
3. The method according to claim 2 , wherein the cancer is a hematological cancer.
4. The method according to claim 2 , wherein the cancer is a solid tumor cancer.
5. The method according to claim 4 , wherein the solid tumor cancer is breast, lung, prostate, ovarian, or pancreatic cancer.
6. The method according to claim 1 , wherein the trispecific antigen-binding protein is administered to the individual in combination with a chemotherapy, hormone therapy, radiotherapy, gene therapy, or immunotherapy.
7. The method according to claim 1 , wherein the trispecific antigen-binding protein is administered to the individual in combination with an anti-diarrheal agent, anti-emetic agent, analgesic, opioid, and/or non-steroidal anti-inflammatory agent.
8. The method according to claim 1 , wherein the first domain comprises complementary determining regions (CDRs) selected from the group consisting of muromonab-CD3 (OKT3), otelixizumab (TRX4), teplizumab (MGA031), visilizumab (Nuvion), SP34, X35, VIT3, BMA030 (BW264/56), CLB-T3/3, CRIS7, YTH12.5, F111-409, CLB-T3.4.2, TR-66, WT32, SPv-T3b, 11D8, XIII-141, XIII-46, XIII-87, 12F6, T3/RW2-8C8, T3/RW2-4B6, OKT3D, M-T301, SMC2, F101.01, UCHT-1, and WT-31.
9. The method according to claim 1 , wherein the first domain is humanized or human.
10. The method according to claim 1 , wherein the first domain is specific for CD3 epsilon.
11. The method according to claim 1 , wherein the first domain has crossreactivity with cynomolgus CD3.
12. The method according to claim 1 , wherein the third domain specifically binds to EGFR.
13. The method according to claim 1 , wherein the third domain specifically binds to PSMA.
14. The method according to claim 1 , wherein the third domain specifically binds to HER2.
15. The method according to claim 1 , wherein the third domain specifically binds to MSLN.
16. The method according to claim 1 , wherein linkers L1 and L2 each independently comprises a sequence selected from the group consisting of: (GS) n (SEQ ID NO: 49), (GGS) n (SEQ ID NO: 50), (GGGS) n (SEQ ID NO: 51), (GGSG) n (SEQ ID NO: 52), (GGSGG) n (SEQ ID NO: 53), or (GGGGS) n (SEQ ID NO: 54), wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
17. The method according to claim 1 , wherein linkers L1 and L2 are each independently (GGGGS) 4 (SEQ ID NO: 55) or (GGGGS) 3 (SEQ ID NO: 56).
18. The method according to claim 1 , wherein the protein has an elimination half-time of at least about 50 hours.
19. A method for treating a disease, disorder or condition associated with PSMA in an individual, comprising administrating a trispecific antigen-binding protein to the individual in need thereof, wherein said protein comprises
(a) a first domain (A) which comprises a single chain variable fragment (scFv) that specifically binds to human CD3;
(b) a second domain (B) which comprises a single domain antibody (sdAb) that binds human serum albumin; and
(c) a third domain (C) which comprises a sdAb that specifically binds to a target tumor antigen that is EGFR, PSMA, HER2, or MSLN, wherein the domains are linked in the order H2N—(C)—(B)—(A)—COOH, or by linkers L1 and L2, and wherein the protein is less than about 60 kDa.
20. A method for treating a disease, disorder or condition associated with MSLN in an individual, comprising administrating a trispecific antigen-binding protein to the individual in need thereof, wherein said protein comprises
(a) a first domain (A) which comprises a single chain variable fragment (scFv) that specifically binds to human CD 3 ;
(b) a second domain (B) which comprises a single domain antibody (sdAb) that binds human serum albumin; and
(c) a third domain (C) which comprises a sdAb that specifically binds to a target tumor antigen that is EGFR, PSMA, HER2, or MSLN, wherein the domains are linked in the order H 2 N—(C)—(B)—(A)—COOH, or by linkers L1 and L2, and wherein the protein is less than about 60 kDa.
21. A method for stimulating the immune system of an individual, comprising administrating a trispecific antigen-binding protein to the individual in need thereof, wherein said protein comprises
(a) a first domain (A) which comprises a single chain variable fragment (scFv) that specifically binds to human CD3;
(b) a second domain (B) which comprises a single domain antibody (sdAb) that binds human serum albumin; and
(c) a third domain (C) which comprises a sdAb that specifically binds to a target tumor antigen that is EGFR, PSMA, HER2, or MSLN, wherein the domains are linked in the order H 2 N—(C)—(B)—(A)—COOH, or by linkers L1 and L2, and wherein the protein is less than about 60 kDa.